Journals / Medicine Science / 2015 / Cilt: 4 - Sayı: 2

Is Irisin an Anticarcinogenic Peptide?

Pages
2172–2180
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results show that the cytotoxic effects of irisin on prostate cancer cells are not dependent on androgen receptor mechanism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Irisin is thought an anti obesity hormone, which regulates body weight and metabolism, including insulin resistance.
📊
Key Findings & Data:In the present study, 0.1, 1, 10 and 100 nM concentrations of irisin were applied to human prostate cancer cells with androgen receptor positive (LNCaP) and androgen receptor negative (DU-145, PC3).
💡
Conclusion & Impact:These results show that the cytotoxic effects of irisin on prostate cancer cells are not dependent on androgen receptor mechanism.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Irisin is thought an anti obesity hormone, which regulates body weight and metabolism, including insulin resistance. It is known that obesity is a risk factor in the development of cancer. This study was designed to evaluate whether there is a role of irisin on viability of human prostate cancer cells. In the present study, 0.1, 1, 10 and 100 nM concentrations of irisin were applied to human prostate cancer cells with androgen receptor positive (LNCaP) and androgen receptor negative (DU-145, PC3). Effects of irisin were determined using 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. At the end of study, all concentrations of irisin reduced viability in the three types of prostate cells, but only 10 and 100 nM concentrations of the irisin caused a significant decreases (p<0.05). Consequently, high concentrations of irisin in both androgen receptor positive and androgen receptor negative cell lines reduced cell viability. These results show that the cytotoxic effects of irisin on prostate cancer cells are not dependent on androgen receptor mechanism.

🔖

Cite This Article

TEKİN, S., ERDEN, Y., SANDAL, S., YILMAZ, B. (2015). Is Irisin an Anticarcinogenic Peptide?. Medicine Science, Cilt: 4 - Sayı: 2, 2172–2180. https://ajindex.com/articles/277952

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Moon HS, Chung CS, Lee HG, Kim TG, Choi YJ, Cho CS. Inhibitory effect of (-)- epigallocatechin-3-gallate on lipid accumulation of 3T3-L1 cells. Obesity (Silver Spring). 2007;15(11):2571-82
  2. Tao W, Lagergren J. Clinical management of obese patients with cancer. Nature reviews Clinical oncology. 2013;10(9):519-33
  3. Genc Z, Tekin S, Sandal S, Sekerci M, Genc M. Synthesis and DFT studies of structural and some spectral parameters of nickel(II) complex with 2-(2- hydroxybenzoyl)-N-(1-adamantyl) hydrazine carbothioamide. Res Chem Intermed. 2014:1-12. (article in press)
  4. Koyunoğlu F, Tekin S, Konar V, Sandal S. İnsan meme kanseri hücre serileri (MCF-7) üzerine apelin-13'ün etkilerinin araştırılması: In vitro bir çalışma. İnönü Üniversitesi Sağlık Bilimleri Dergisi. 2013;1(1):23-8
  5. Tekin S, Sandal S, Colak C. Effects of Apelin-13 on Human Prostate Cancer Lines [Insan Prostat Kanseri Hucre Serilerinde Apelin-13'un Etkileri]. Med-Science. 2014;3(3):1427-41
  6. Karagoz Genc Z, Tekin S, Sandal S, Genc M. Theoretical calculations, cytotoxic evaluation, and molecular docking studies of 4-(1-adamantyl)-5-[2-(3- hydroxynapthyl)]-2H-1,2,4-triazole-3(4H)-thione as a novel chemotherapeutic agent. Res Chem Intermed. 2014:1-16. (article in press)
  7. TC Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu http://www.kanser.gov.tr/dairefaaliyetleri/kanser-istatistikleri.html erişim tarihi 01.10.2014 8. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87(9):652-61
  8. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388-413
  9. Chan JM, Stampfer MJ, Giovannucci, gt, L. E. What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol. 1998;8(4):263-73
  10. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostatespecific analysis ratio, age-specific reference ranges, and PSA density. Urology. 1995;46(6):779-84
  11. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-alpha-dependent myokine that drives brownfat-like development of white fat and thermogenesis. Nature